Roche has secured U.S. Food and Drug Administration clearance for Elecsys pTau217, a plasma-based blood test designed to help physicians detect amyloid pathology linked to Alzheimer’s disease. The test targets adults aged 55 and above who present with cognitive decline symptoms, giving both primary care providers and specialists a shared diagnostic tool built on identical validated thresholds.

Co-developed with Eli Lilly and Company, ElecsyspTau217 stands out as the only FDA-cleared single-biomarker blood test capable of both confirming and ruling out amyloid pathology across care settings using one consistent cutoff standard—an approach Roche calls its “Power of One” strategy.

Dan Malarek, President and CEO of Roche Diagnostics North America, called the clearance a milestone that could bring diagnostic evaluation closer to patients and strengthen clinicians’ confidence in charting next steps. Carole Ho of Lilly Neuroscience emphasized the collaboration’s goal: narrowing the gap between symptom onset and diagnostic answers for families affected by the disease.

Roughly three-quarters of people living with dementia remain undiagnosed, and existing detection methods—PET scans and cerebrospinal fluid testing—are often expensive, invasive, and limited to specialty settings. Elecsys pTau217 offers a less invasive alternative that fits into current lab workflows, potentially identifying patients earlier and flagging who needs further imaging or specialist referral.

The test returns positive, intermediate, or negative results and is built to run on Roche’s existing network of more than 4,500 cobas laboratory instruments across the U.S., allowing rapid rollout without new equipment investment. Notably, this marks the fourth FDA-cleared blood-based Alzheimer’s biomarker test overall—and the second cleared within the same week—reflecting accelerating momentum toward accessible, blood-based neurological diagnostics.

Written By: Sayan Das 

Graphics by: Pramit Hazra